• Skip to content
  • Skip to footer
Therachon

Therachon

  • About Us
    • Management Team
    • Board of Directors
    • Partners
  • Our Focus
    • Achondroplasia
    • Short Bowel Syndrome
    • Pipeline
  • News & Media
  • Contact Us

News & Media

News & Media
Therachon to Present Data from Ongoing Phase II Study of Apraglutide for Short Bowel Syndrome (SBS) at Digestive Disease Week

May 17, 2019

Therachon to Present Data from Ongoing Phase II Study of Apraglutide for Short Bowel Syndrome (SBS) at Digestive Disease Week

Data to be presented from Phase II study of two patients with short bowel syndrome in an ongoing study of apraglutide BASEL, Switzerland, May 17, 2019 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biopharmaceutical…

Pfizer Acquires Clinical-Stage Biotech Therachon

May 8, 2019

Pfizer Acquires Clinical-Stage Biotech Therachon

Expands Pfizer’s rare disease portfolio with potential first-in-class therapy for achondroplasia, a genetic condition and the most common form of short-limb dwarfism NEW YORK & BASEL, Switzerland–Pfizer (NYSE: PFE) today…

Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

March 25, 2019

Therachon Presents Data from Preclinical and Phase I clinical Studies of Apraglutide for the Treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

– Results establish favorable safety profile and show the potential for efficacy with once-weekly dosing of a next generation GLP-2 analog – In head-to-head rat studies, apraglutide displayed a longer…

Therachon Strengthens Board of Directors with the Appointment of Industry Leaders Sandip Kapadia and Patrick Machado

January 30, 2019

Therachon Strengthens Board of Directors with the Appointment of Industry Leaders Sandip Kapadia and Patrick Machado

BASEL, Switzerland, Jan. 30, 2019 – Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced the appointments of Sandip…

Therachon is Granted Orphan Drug Designation by US FDA for Apraglutide for the Treatment of Short Bowel Syndrome

January 16, 2019

Therachon is Granted Orphan Drug Designation by US FDA for Apraglutide for the Treatment of Short Bowel Syndrome

BASEL, Switzerland, Jan. 16, 2019  — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative treatments for serious rare conditions, today announced that the U.S. Food…

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Next Page »

Footer

  • About Us
  • Our Focus
  • Contact Us
  • News & Media
  • Join Us
Therachon logo

Terms of Use | Privacy Policy

Copyright © Therachon. 2019 All Rights Reserved.